Nedaplatin infusion induced marked QT prolongation from 444 ms to 567 ms and polymorphic ventricular tachycardia in a 41-year-old woman with metastatic carcinoma.
Case Report (n=1)
No
Nedaplatin infusion can induce severe QT prolongation and polymorphic ventricular tachycardia, highlighting the need for systematic ECG monitoring during its administration.
Effect estimate: QTc prolonged from 444 ms to 567 ms
Absolute Event Rate: 567% vs 444%
Nedaplatin (NDP), a cisplatin derivative, is widely employed in the treatment of solid tumours. Commonly reported adverse effects include hypersensitivity, myelosuppression and nephrotoxicity. To date, QT-interval prolongation and polymorphic ventricular tachyarrhythmia have not been attributed to NDP. A 41-year-old Asian woman was referred to our institution with abdominal pain, diarrhoea and vomiting. Percutaneous biopsy confirmed a diagnosis of high-grade serous carcinoma with widespread metastatic dissemination. She sequentially received a PD-1 inhibitor, paclitaxel and NDP. Twenty minutes after NDP infusion commenced she developed abdominal pain, palpitations, nausea and hypotension (68/39 mmHg). ECG disclosed marked QT prolongation, polymorphic ventricular tachycardia and Mobitz type I second-degree atrioventricular block. Advanced life-support measures were instituted immediately. Following withdrawal of the implicated agent and substitution with carboplatin, she remained asymptomatic during 48 h of monitoring. We report the case of marked QT-interval prolongation and polymorphic ventricular tachycardia temporally related to NDP administration. Clinicians should therefore monitor the electrocardiogram closely during NDP therapy, particularly in patients receiving polypharmacy.
Li et al. (Wed,) conducted a case report in Metastatic high-grade serous carcinoma (n=1). Nedaplatin vs. Carboplatin substitution after adverse event was evaluated on QT interval prolongation and polymorphic ventricular tachycardia following Nedaplatin infusion (QTc prolonged from 444 ms to 567 ms). Nedaplatin infusion induced marked QT prolongation from 444 ms to 567 ms and polymorphic ventricular tachycardia in a 41-year-old woman with metastatic carcinoma.